Competitive Intelligence for Cancer Research Centers

Cancer research centers sit where science becomes care. Comprehensive centers bring academic innovation and early-phase trials; community centers deliver treatment close to patients and increasingly take part in research. Both face the same pressure: new drugs, new formats and new diagnostic requirements arrive faster than operations can adapt. Competitive intelligence (CI) for cancer research centers helps leaders decide which trials to open, which approvals to prepare for and where to invest. For a service overview, see Oncology Resource Group’s page for cancer research centers.

Updated October 8, 2026.

Why centers need their own kind of intelligence

Sponsors and CROs track competitors to win market share. Centers track the same landscape for different reasons: to judge trial feasibility, to avoid splitting a limited patient pool across competing studies, to staff and equip for new therapies, and to know what will change standard care at their own bedside. The examples below, all from the past 18 months, show the kinds of events that matter.

• New formulations change infusion capacity. Tecentriq Hybreza, approved by the FDA on September 12, 2024, is injected in about seven minutes compared with 30-60 minutes for the IV form (Drugs.com). Merck states that subcutaneous Keytruda takes one minute every three weeks or two minutes every six weeks (Merck). Fewer chair-hours per patient affects scheduling, staffing and pharmacy workflow.
• New modalities need operational readiness. On March 5, 2026, FDA approved Tecvayli plus Darzalex Faspro for relapsed or refractory myeloma. Tecvayli carries a boxed warning for cytokine release syndrome and neurotoxicity and is distributed under a REMS program (CURE). A BCMA CAR-T therapy, anito-cel, has an FDA action date of December 23, 2026 (Kite/Gilead). Centers need trained teams, monitoring protocols and bed capacity before these therapies arrive.
• Biomarkers and diagnostics decide eligibility. On May 15, 2026, FDA approved adjuvant Tecentriq for ctDNA-positive muscle-invasive bladder cancer after cystectomy, together with the Signatera companion diagnostic (ONS Voice). In breast cancer, FDA approved Enhertu for HR-positive HER2-low and HER2-ultralow disease on January 27, 2025 (FDA), which changes which pathology results matter.
• Safety monitoring requirements move with the label. The May 15, 2026 FDA approvals of Enhertu in early breast cancer carry a boxed warning for interstitial lung disease (FDA), a reminder that moving a drug earlier in the disease course changes who monitors it and for how long.
• Competing trials target the same patients. Several Phase 3 programs compare newer bispecific antibodies with pembrolizumab-based regimens in first-line NSCLC, including HARMONi-3, HARMONi-7, ROSETTA Lung-202 and Symbiotic-Lung-01 (BioNTech 6-K; Summit Q2 report). A center with limited lung cancer volume has to choose.
• Trials get stopped. ClinicalTrials.gov lists both Phase 3 abelacimab trials in cancer-associated thrombosis, ASTER and MAGNOLIA, as terminated by the sponsor, with 1,150 and 417 participants enrolled (ClinicalTrials.gov). Roche discontinued its anti-TIGIT antibody tiragolumab in July 2025 (ApexOnco). Sites that had committed capacity to those programs felt it.
• Practice-changing data arrives continuously. At WCLC 2026, a post hoc eight-year ADAURA analysis reported overall survival of 79% vs 64% with adjuvant osimertinib in stage IB-IIIA EGFR-mutated NSCLC (OncLive), which is relevant to how early-stage EGFR testing is prioritized.

What a center-focused CI program should cover

1. Trial landscape and feasibility. Which competing studies are enrolling the same population, what the eligibility criteria are, and where your center can realistically contribute. See our guide to pipeline tracking.
2. Upcoming approvals and launches. A calendar of FDA action dates and expected filings, with the operational requirements each new therapy brings.
3. Standard-of-care shifts. How treatment sequencing is changing in your priority cancers. See treatment algorithm maps.
4. Diagnostics and biomarker testing. New companion diagnostics and testing expectations that tumor boards and pathology will need to meet.
5. Conference intelligence. What was presented, how experts reacted, and what it means for patients you treat. See conference coverage. Upcoming meetings include ESMO (October 23-27, 2026) and ASH (December 12-15, 2026).
6. Sponsor and partnership activity. Which companies are expanding programs, which are retreating, and where partnership opportunities may open.

Who inside a center uses it

• Growth and strategy leaders use it for program development, partnerships and service-line planning.
• Research operations teams use it for portfolio planning, feasibility and site-selection conversations with sponsors.
• Clinical care leaders and physicians use it to understand which developments will change practice and which will not.
• Pharmacy and nursing leaders use it to prepare for new formulations, monitoring requirements and supportive-care needs.

Comprehensive centers often want depth in early-phase and novel mechanisms. Community centers more often want clear guidance on what is practice-ready and what is still investigational. A good program serves both without burying either in detail.

Building a program that works

1. Pick priority cancers and service lines. Coverage that tries to include everything ends up shallow.
2. Tie intelligence to scheduled decisions. Trial committee meetings, formulary reviews and budget cycles give CI a deadline.
3. Separate fact from claim. Record whether an item comes from a regulator, a registry, a paper or a company, and whether numbers are final or topline.
4. Use a short, consistent format. A one-page summary with an explicit implications line gets read.
5. Track what did not happen. Terminated trials, delayed filings and withdrawn applications affect your pipeline too.

Common pitfalls

• Treating registry dates as readout dates. Estimated primary completion is when data collection ends, not when results appear.
• Assuming approval means availability. Distribution programs, diagnostics and payer rules can delay real-world use.
• Relying on one secondary source. Dates and figures vary between outlets; check the regulator or the filing.

Next step

If your center is weighing how to structure oncology intelligence for strategy, research operations and clinical care, Oncology Resource Group describes its approach for cancer research centers here: Oncology Resource Group: Cancer Research Centers. You can also request information from us directly.

Keep reading: competitive intelligence for pharmaceutical biotech, what is oncology competitive intelligence and treatment algorithm maps.

This article is for informational and competitive-intelligence purposes only and is not medical advice. Approvals, labels and trial results change; verify details against current prescribing information and primary sources.